Lisanti Capital Growth LLC Invests $3.95 Million in Guardant Health, Inc. $GH

Lisanti Capital Growth LLC purchased a new position in shares of Guardant Health, Inc. (NASDAQ:GH) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 38,665 shares of the company’s stock, valued at approximately $3,949,000.

Other large investors also recently modified their holdings of the company. V Square Quantitative Management LLC purchased a new stake in shares of Guardant Health during the 4th quarter worth approximately $27,000. Chesapeake Asset Management LLC purchased a new stake in shares of Guardant Health during the 4th quarter worth approximately $28,000. Thurston Springer Miller Herd & Titak Inc. bought a new position in Guardant Health in the 4th quarter worth approximately $31,000. Elyxium Wealth LLC bought a new position in Guardant Health in the 4th quarter worth approximately $35,000. Finally, First Pacific Financial bought a new position in Guardant Health in the 4th quarter worth approximately $43,000. Hedge funds and other institutional investors own 92.60% of the company’s stock.

Guardant Health Price Performance

Shares of NASDAQ:GH opened at $118.95 on Friday. The firm has a fifty day moving average price of $91.15 and a two-hundred day moving average price of $98.94. Guardant Health, Inc. has a one year low of $36.36 and a one year high of $121.01. The company has a market cap of $15.77 billion, a price-to-earnings ratio of -35.09 and a beta of 1.48.

Guardant Health (NASDAQ:GH) last announced its quarterly earnings results on Thursday, February 19th. The company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.43) by ($0.07). The business had revenue of $281.27 million for the quarter, compared to analysts’ expectations of $269.74 million. During the same period last year, the firm posted ($0.62) earnings per share. Guardant Health’s revenue for the quarter was up 39.4% on a year-over-year basis. Equities research analysts expect that Guardant Health, Inc. will post -2.92 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research analysts recently commented on GH shares. Wells Fargo & Company raised their price objective on shares of Guardant Health from $120.00 to $125.00 and gave the stock an “overweight” rating in a report on Friday, February 20th. Guggenheim raised their price objective on shares of Guardant Health from $115.00 to $135.00 and gave the stock a “buy” rating in a report on Monday, January 26th. Canaccord Genuity Group raised their price objective on shares of Guardant Health from $125.00 to $135.00 and gave the stock a “buy” rating in a report on Friday, February 20th. Barclays raised their price objective on shares of Guardant Health from $115.00 to $120.00 and gave the stock an “overweight” rating in a report on Friday, May 8th. Finally, Robert W. Baird started coverage on shares of Guardant Health in a report on Tuesday, February 17th. They issued an “outperform” rating and a $120.00 price objective for the company. Nineteen research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $129.00.

Insider Transactions at Guardant Health

In other Guardant Health news, Director Ian T. Clark sold 6,876 shares of the firm’s stock in a transaction on Wednesday, May 20th. The shares were sold at an average price of $106.90, for a total value of $735,044.40. Following the completion of the transaction, the director directly owned 2,975 shares of the company’s stock, valued at $318,027.50. This trade represents a 69.80% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider John G. Saia sold 20,000 shares of the firm’s stock in a transaction on Wednesday, May 20th. The shares were sold at an average price of $106.51, for a total transaction of $2,130,200.00. Following the completion of the transaction, the insider directly owned 45,950 shares of the company’s stock, valued at approximately $4,894,134.50. The trade was a 30.33% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 296,838 shares of company stock worth $31,878,906. 5.60% of the stock is owned by corporate insiders.

Guardant Health Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.